Anika Therapeutics, Inc.
Company Stats
- Market Cap
- $263.1M
- as of Sep 30, 2026
- Shares Outstanding
- 13.4M
- Free Float
- 76.2%
Income Statement
- Revenue
- $112.8M
- Operating Income
- -$11.1M
- Net Income
- -$10.9M
- EBITDA
- -$5.7M
Cash Flow
- Free Cash Flow
- $4.4M
- FCF Yield
- 1.7%
- Owner FCF Yield
- -2.2%
Balance Sheet
- Cash & Equivalents
- $57.5M
Returns & Capital
- Share Repurchases
- $9.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $112.8M | $4.4M | 3.9% |
| FY2024 | $119.9M | -$2.3M | -1.9% |
| FY2023 | $120.8M | -$7.2M | -6.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 25, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges